Metabolic syndrome and cardiometabolic risk factors.

This article reviews the evidence that demonstrates that individuals with the MetS are at increased risk for CVD incidence and mortality and discusses these debated issues.
PMID: 24484465 [PubMed - in process]

Source: Current Vascular Pharmacology - January 31, 2014 Category: Drugs & Pharmacology Authors: Papakonstantinou E, Lambadiari V, Dimitriadis G, Zampelas A Tags: Curr Vasc Pharmacol Source Type: research